This institutional-based cross-sectional study examines the burden of self-medication during pregnancy in a middleincome country setting and the impact on fetal wellbeing. Using a blend of open-ended and indication-oriented questionnaires, 346 pregnant women at term were interviewed about their pregnancy complaints and drug intake. Inferential statistical data analysis was employed with level of significance (a) set at 0.05. Excluding routine supplements and vaccinations, 251 (72.5%) women used medicines, of whom 79 (31.5%) had self-medicated. Consuming drugs without prescription was associated with increased US Food & Drug Administration (FDA) risk category ( 2 ¼ 8.375; P ¼ 0.015). There is therefore a need to scale up efforts towards educating women about the dangers of self-medication, while also introducing effective restrictive policies on over-the-counter drug sales.
Introduction
Since the tragedy of thalidomide, 1 the need for rational prescription and cautious consumption of drugs during pregnancy is well understood. 2 As a guide to prescribers, drugs used in pregnancy have been classified according to risk categories. [3] [4] [5] Nonetheless, inappropriate drug use by pregnant women in low-and middle-income countries (LMICs) persists and self-medication is frequent. 6, 7 There is a dearth of information as to what propels pregnant women to self-medicate, the pattern of drug use, the extent of self-medication and its impact on fetal development.
Methods
Our study was conducted at the department of Obstetrics and Gynaecology, Ekiti State University Teaching Hospital (EKSUTH), Ado-Ekiti, Nigeria between 1 April and 31 July 2014. EKSUTH is a tertiary health facility located in the capital city of Ekiti State, southwest Nigeria and serves as the referral centre for high-risk pregnancies and complicated labour. Its average annual pool of antenatal attendees is 3600 and the hospital delivery rate is 2500 per year.
Permission for the conduct of the study was sought and obtained from the Ethics Committee of EKSUTH.
An estimation of sample size was calculated using a previous report of 71.3% prevalence of medication use among pregnant women. 8 With a 10% allowance for non-response, an acceptable error margin of 0.05, a standard normal deviate of 1.96 and 95% level of confidence, it was calculated that 346 participants would be needed to power the study adequately. All eligible pregnant women (gestational age range, 37-42 weeks) booked for antenatal appointments, who gave an informed written consent to participate in the survey, were sequentially recruited until the required sample size was reached.
An interviewer-administered, semi-structured questionnaire was used for data collection concerning drugs consumed by the women during their pregnancy. The questionnaire was developed from previous studies and was specifically conceptualised to fit the study setting. It had three sections: information on biodata of respondents; modified treatment indication-oriented questions (based on 24 common pregnancy disorders which included malaria because of its peculiarity to the study setting); and sets of open-ended questions as recommended by the Collaborative Group on Drug Use in Pregnancy. 9, 10 The developed questionnaire was pre-tested in the antenatal clinic for content validity and clarity prior to commencement of the study. Based on feedback from the pre-test, appropriate corrections were made to the questionnaire. Pregnant women used for the pre-test were, however, excluded from participating in the actual study to avoid data contamination. Interviewers were resident doctors purposely trained for the study. Since all antenatal attendees are routinely on iron and folic acid supplements owing to subsisting high prevalence of anaemia in pregnancy in the study region, haematinics and regular vaccinations were excluded from the drug consumption survey.
Drugs used by participants were categorised according to the FDA risk classification (Table 1) . 3 Drugs consumed were also grouped as prescribed by a health practitioner or bought over-the-counter (OTC). Information about drug consumption was obtained at the interview, but additional information was extracted from respective medical files. The number of times in which a drug was either purchased based on prescription or for self-medication was noted.
The collected data were entered into computer software, Statistical Package for Social Sciences (SPSS) version 17. The data were cleaned and analysed using both univariate and multivariate statistical methods. Frequency tables were generated to reflect the sociodemographic characteristics of respondents, the common complaints during pregnancy and medicine used by the pregnant women based on FDA classification. Chisquare ( 2 ) was used to test for association between OTC drug purchase and increased FDA risk category. Logistic regression analysis was equally employed to identify sociodemographic factor(s) that predicts selfmedication through OTC drug purchase. The level of significance (a) was set at 0.05.
Results
As presented in Table 2 , of the 346 women interviewed, 131 (37.9%) were nulliparous. Only 78 (22.5%) had the index pregnancy unplanned. Table 3 displays the overall pattern of complaints by study participants; this prevalence was 272/346 (78.6%). Fever topped the list, occurring in 179 (51.7%) of respondents; next was the complaint of oedema by 69 (19.1%), followed by headache in 56 (16.2%) . Vaginal discharge was reported among 49 (14.2%); 30 (8.7%) complained of anorexia or vomiting. Whereas none of the participants had epilepsy, two (0.6%) were diabetic and eight (2.3%) had hypertension in pregnancy.
Excluding routine haematinics (iron and folic acid supplements) and vaccinations, the prevalence of use of medications by respondents was 251/346 (72.5% of the total number of respondents, but 92.3% of those who had complaints). Of the medication consumed, 172 (68.5%) were based on prescription by health practitioners while 79 (31.5%) were by OTC purchase.
Details of drugs consumed according to risk category are shown in Tables 4 and 5. The consumption of drugs with increased FDA risk category was Table 1 . Drugs according to FDA risk classification.
FDA risk category Description
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters) B
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and wellcontrolled studies in pregnant women C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and wellcontrolled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits significantly greater for OTC medications ( 2 ¼ 8.375; P ¼ 0.015). No sociodemographic predictors were statistically significant.
Discussion
Our study shows that more than 75% of our respondents had medical and/or gynaecological complaints during their pregnancy, the commonest being fever as in available local reports. 11, 12 Although endemicity of malaria in our region supports the recommendation of routine antenatal administration of intermittent preventive therapy (IPT), 13 it is worrisome that fever is assumed to be due to malaria, often with no testing, and OTC medication taken inappropriately.
Our study noted that four of the 41 different drugs consumed are classified as risk Category D. Most of these were purchased OTC. Although the one respondent who purchased Tinidazole stated that it was not used during the first trimester, this drug is tagged Category X if consumed then. Some of the Category D drugs used by study participants are recorded as being responsible for craniofacial abnormalities, oligohydraminous, ototoxicity, nephrotoxicity and fetal withdrawal syndromes. 14, 15 Self-medication by approximately one-third of our respondents is quite alarming but not surprising in an environment with poor drug sales regulation. In fact, in Nigeria, virtually all drugs can be procured without prescription. This situation may not be peculiar to Nigeria alone, as a 28.8% prevalence of self-medication during pregnancy was reported in South Africa and 52.2% in Ethiopia. 7, 16 Our study found that self-medication is associated with increased risk to the fetus. An earlier African study came to the same conclusion. 7 This suggests a need to tighten policy on OTC drugs while at the same time scaling up education of women concerning drug safety during pregnancy.
Without doubt, interview studies are characterised by inherent memory lapses and under-reporting; thus under-estimation of drug consumption is likely. Furthermore, many respondents were uncertain concerning the exact timing of consumption of OTC drugs, obviously important regarding first trimester Category X drugs.
In conclusion, OTC drugs need strict controls and the sale of medication of Categories D and X to pregnant women should carry a legal penalty. (2:2); Acetylsalysalic acid (0:1); Doxycycline (1:0); Streptomycin (0:1) 7 (2.2%) 4 (9.8%) X Uncertain -*Cough mixture contains chlopheniramine, pseudoephedrine and dextromethophan or guaifenesin. ySulphadoxine/pyrimethamine risk increase from 'C' to 'D' when consumed close to term. zTinidazole risk increases from 'C'' to 'X' if consumed in the first trimester. 
